University of Auckland senior research fellow Jeff Smaill first visited China in 2012 as part of a team of 15 scientists from the Maurice Wilkins Center, one of New Zealand’s centers of excellence, to ...

The green light from the European Commission comes a few months after pan-FGFR inhibitor Balversa (erdafitinib) was cleared for the same indication in the US, with a different label than the drug ...

Australia: A recent study published in the New England Journal of Medicine highlighted the potential benefits of oral ...

The FGFR inhibitor had been granted accelerated approval in 2022 as a treatment for bile duct cancer (under the trade name Truseltiq), but that approval was withdrawn earlier this year.

Erdafitinib is a once-daily, oral FGFR kinase inhibitor, which works by inhibiting the activity of FGFR3 alterations in cancer cells and has been shown to extend overall survival compared to ...